Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 7/20 | 0.82 |
| ▸ | MMP13 | P45452 | 6/20 | 0.82 |
| ▸ | MMP8 | P22894 | 5/20 | 0.82 |
| ▸ | MMP1 | P03956 | 2/20 | 0.73 |
| ▸ | MMP7 | P09237 | 1/20 | 0.73 |
| ▸ | CASP1 | P29466 | 2/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | ACLY | P53396 | 1/20 | 0.47 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8487453 | 0.85 | MMP8 (0.70) | MMP12MMP13MMP8MMP1MMP7 | |
| SCHEMBL8101285 | 0.84 | MMP12 (0.61) | MMP12MMP13MMP8MMP1MMP7 | |
| SCHEMBL5281032 | 0.83 | MMP8 (0.62) | MMP12MMP13MMP8MMP1MMP7 | |
| SCHEMBL3207695 | 0.83 | MMP8 (0.60) | MMP12MMP13MMP8MMP1MMP7 | |
| SCHEMBL4174812 | 0.81 | MMP8 (0.75) | MMP12MMP13MMP8MMP1MMP7 | |
| SCHEMBL4170728 | 0.80 | MMP8 (0.56) | MMP12MMP13MMP8MMP1MMP7 | |
| SCHEMBL15754219 | 0.79 | L3MBTL1 (0.64) | MMP12MMP13MMP8MMP1MMP7 | |
| SCHEMBL11108606 | 0.79 | L3MBTL1 (0.59) | MMP12MMP13MMP8MMP1MMP7 | |
| SCHEMBL9002519 | 0.79 | MMP8 (0.59) | MMP12MMP13MMP8MMP1MMP7 | |
| SCHEMBL3836194 | 0.78 | MMP8 (0.58) | MMP12MMP13MMP8MMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215893-A1 | Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin | SHISEIDO COMPANY LTD (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1884230-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215893-A1 | Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin | CUTA, STOM, MTOR | MMP12 1873/4885MMP13 1841/4885MMP8 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.